Cargando…

Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy

SIMPLE SUMMARY: Gastric adenocarcinoma (GAC) is most commonly classified based on a system developed by the Cancer Genome Atlas in 2014. However, this subtyping system cannot efficiently identify suitable candidates for immunotherapy. Because GAC is highly heterogeneous and closely related to CRC at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiangyan, Ye, Yuhan, Vega, Kenneth J., Yao, Jiannan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367605/ https://www.ncbi.nlm.nih.gov/pubmed/35954402 http://dx.doi.org/10.3390/cancers14153740

Ejemplares similares

A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
por: Bigelow, Emma, et al.
Publicado: (2022)

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
por: Ren, Qianqian, et al.
Publicado: (2020)

Deconvolution Analysis for Classifying Gastric Adenocarcinoma Patients Based on Differential Scanning Calorimetry Serum Thermograms
por: Vega, Sonia, et al.
Publicado: (2015)

SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
por: Li, Dezhao, et al.
Publicado: (2022)

Clinically conserved genomic subtypes of gastric adenocarcinoma
por: Jeong, Yun Seong, et al.
Publicado: (2023)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
por: Kang, Junwei, et al.
Publicado: (2022)

Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy
por: Song, Yang, et al.
Publicado: (2020)

Dysregulated ferroptosis‐related genes indicate potential clinical benefits for anti–PD‐1/PD‐L1 immunotherapy in lung adenocarcinoma
por: Zhou, Min, et al.
Publicado: (2021)

A potential EBV-related classifier is associated with the efficacy of immunotherapy in gastric cancer
por: Xu, Yun-Yun, et al.
Publicado: (2022)

Histological subtype of gastric adenocarcinoma: two cases of mixed fundic and pyloric mucosa-type adenocarcinoma
por: Takahashi, Haruhiko, et al.
Publicado: (2020)

Adenocarcinoma with Mixed Subtypes in the Early and Advanced Gastric Cancer
por: Zhao, Xixian, et al.
Publicado: (2021)

Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
por: Ling, Chen, et al.
Publicado: (2022)

Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes
por: Duan, Guangliang, et al.
Publicado: (2023)

The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
por: Chen, Ke, et al.
Publicado: (2021)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Gastric adenocarcinoma with germ cell tumor components: a rare case report
por: Han, Xu, et al.
Publicado: (2022)

CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer
por: Jiang, Qiuyu, et al.
Publicado: (2023)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

Therapeutic strategies targeting uPAR potentiate anti–PD-1 efficacy in diffuse-type gastric cancer
por: Qin, Long, et al.
Publicado: (2022)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma
por: Phruttinarakorn, Bantita, et al.
Publicado: (2020)

Operable gastric adenocarcinoma with different histological subtypes: Cancer-specific survival in the United States
por: Lin, Chun-Lin, et al.
Publicado: (2019)

MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response
por: Zhang, Bin, et al.
Publicado: (2023)

S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8(+) T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
por: Li, Huihuang, et al.
Publicado: (2023)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue
por: Heo, You Jeong, et al.
Publicado: (2019)

Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma
por: Wei, Shuxun, et al.
Publicado: (2022)

Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis
por: Greene, Michael W., et al.
Publicado: (2022)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

Construction of subtype classifiers and validation of a prognostic risk model based on hypoxia-associated lncRNAs for lung adenocarcinoma
por: Hui, Hongliang, et al.
Publicado: (2023)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

The Consensus Molecular Subtypes of Colorectal Cancer
por: Guinney, Justin, et al.
Publicado: (2015)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m0tq4cumo1802vdp3d0dl7dflt